AIM ImmunoTech AIM Stock News

AIM ImmunoTech Inc (NYSEAMERICAN: AIM) is heading back up in the market this morning after a bit of profit taking yesterday. The wild ride in the value of the stock started a few sessions ago when the company announced that it would assess its flagship candidate, Ampligen, as a potential option in the treatment of the novel coronavirus.

The stock continued to fly when the company announced that Ampligen would be testing in Japan as a treatment relatively soon. While profit taking took place at the top, that move was normal and expected. Nonetheless, while the stock has seen gains in multiples as of late, the ride is far from over and more gains are likely ahead of us. Here’s how I see it:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

AIM Stock Gains Are Far From Over

When thinking about AIM ImmunoTech in the coronavirus space, the company has quite a bit going for it. To start, Ampligen is an immuno-therapy, harnessing the body’s own immune system to be able to combat serious illnesses, ranging from viral infections to cancer.

With that said, while there are tons of companies out there that are working on the development of vaccines, very few are actually working to treat COVID-19 infected patients. Of the very few, AIM was the first to announce that it would be working on a treatment.

Moreover, the treatment shows so much promise that the National Institute of Infectious Disease in Japan decided that it would be willing to take charge of testing. Testing will begin at NIID and the University of Tokyo.

In a recent statement, Thomas K. Equels, CEO at AIM, had the following to offer:

As we have been saying all along, this emerging pandemic is caused by a virus that has nearly identical regulatory RNA sequences to the original SARS coronavirus, known as SARS-CoV-1, in respect to pathogenesis. This means that the prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against the new virus. The WHO has recently renamed this emerging, highly pathogenic virus as SARS-CoV-2.

Ampligen had excellent antiviral activity against the earlier SARS coronavirus in U.S. National Institutes of Health-contracted animal experiments. In those studies of SARS-infected mice, Ampligen stands out as the only drug tested that conferred a significant survival effect: 100% of the Ampligen-treated mice survived, while none of the untreated mice survived. Because SARS-CoV-2 shares many critical similarities with SARS-CoV-1, Ampligen may have an important role to play in developing a protective early-onset therapy for this new highly pathogenic coronavirus in humans, where currently there is no known effective therapy. We are proud to work with Japan’s universally esteemed NIID in the battle to curb this emerging potential pandemic.

Considering the fact that these big players want to get involved, there’s a clear sign that AIM ImmunoTech is onto something here.

Going further, the companies that are in the race to develop a treatment not only have to develop and test a viable option, a process that AIM is working on, but they will have to manufacture the drug.

Manufacturing is a process in and of itself, and manufacturing mass quantities of a new drug can be a challenge. Ultimately, this is a very time consuming process. However, when it comes to AIM, we just brought up another strategic advantage.

Because of the fact that Ampligen has proven effective in a wide range of ailments, and already has an approval for ME/CHFS, the first drug to receive an approval in this indication, the company already has a massive amount of Ampligen produced and on hand.

Considering this, should the drug prove to be effective in the treatment of COVID-19, AIM ImmunoTech will not have to wait on enough Ampligen to be manufactured for commercialization. The company is already sitting on what would likely be enough ampligen to treat those who are currently sick. Moreover, if more needed to be manufactured, there is already a process in place to do so.

The Bottom Line

The bottom line here is that when it comes to the treatment of the Wuhan coronavirus, AIM is already far ahead of its competition. Not only does the company have what may prove to be a great treatment option, it has enough on hand to treat the masses, offering up an incredible opportunity. So, recent profit taking in the stock only opened the door to a discount my friends.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.